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Introduction
A hallmark feature of the National Institute of Neuro  logical 
and Communicative Diseases and Stroke–Alzheimer’s 
Disease and Related Disorders Association criteria for a 
clinical diagnosis of probable Alzheimer’s disease (AD), 
ﬁ  rst established over 25 years ago, was the requirement 
of a dementia syndrome. Th   e clinician then proceeded to 
systematically rule out and exclude other neurological 
and/or medical conditions that might have accounted for 
the observed cognitive decline. Th   is set of criteria as well 
as the Diagnostic and Statistical Manual of Mental 
Disorders  (fourth edition) criteria for a dementia 
syndrome and probable AD [1] were designed to be 
conservative so that a neurodegenerative condition could 
not be established unless cognitive function was suﬃ   -
ciently compromised to interfere with an individual’s 
social and/or occupational function.
Since AD probably develops many years before cogni-
tive symptoms are manifest [2] and cognitive deﬁ  cits are 
evident before the appearance of a full-blown dementia 
syndrome, increasing attention has been focused on mild 
cognitive impairment (MCI) as an intermediary state 
between normal cognition and AD [3,4]. Th  e generally 
accepted criteria for MCI are the presence of a memory 
or other cognitive complaint by an individual or other 
knowledgeable informant, objective deﬁ  cits on standard-
ized objective cognitive tests and the lack of a dementia 
syndrome characterized by intact general intellectual 
func  tion and no signiﬁ  cant  deﬁ   cits in social and/or 
occupational function. As disease-modifying agents are 
developed, the best hope for prevention or cure lies in 
treating the disorder in its earliest stages before the brain 
is severely compromised by multisystem degeneration 
[5].
Eﬀ   orts at earlier detection of AD face signiﬁ  cant 
challenges in improving assessment of the earliest 
cognitive and neuropathological changes associated with 
early AD, identifying those MCI cases that are most likely 
to progress over time, and gauging the progression of 
MCI to a clinical diagnosis of AD. Th  is improvement 
requires assessment tools that are sensitive to subtle 
cognitive changes, as well as measures that are adequate 
in evaluating deterioration in cognitive abilities over 
time. Complicating eﬀ  orts at early diagnosis are the fact 
that not all cases of MCI will progress to dementia, and 
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with AD. Th  is is particularly true in epidemiological 
studies, where the reversion of MCI to non-MCI has 
been as high as 40% [6] – as opposed to the progression 
ranging from 10 to 15% in specialty memory disorders 
clinics and other clinical settings [3,7].
Th  e popular term regarding conversion from MCI to 
dementia of the AD type is probably a misnomer. If one 
has correctly identiﬁ  ed underlying AD in a predementia 
phase, then progression to a clinical diagnosis of AD is 
merely dependent on the individual progressing to a 
particular threshold at which point there is suﬃ   cient 
cognitive and functional impairment to merit the diag-
nosis of a dementia syndrome (provided that the clinician 
can rule out other potential etiologies). In recent years, 
there has been increasing concern that AD is not being 
identiﬁ   ed in its earlier stages because of a failure to 
emphasize the primary episodic memory deﬁ  cit  and 
abnormal biomarkers associated with the disorder, 
speciﬁ   cally volumetric magnetic resonance imaging 
(MRI), positron emission tomography (PET) neuro  imag-
ing, and cerebrospinal ﬂ  uid (CSF) analysis of amyloid β 
or tau proteins [8]. Furthermore, the delineation between 
MCI and dementia that is critical to a diagnosis of AD 
may vary as a function of experience and/or idiosyncratic 
thresholds of an individual clinician in judging whether 
an individual’s cognitive impairment is signiﬁ  cantly 
interfering with social and/or occupational function [9].
What follows is an examination of diﬀ  erent types of 
measures that are sensitive to early AD in the MCI state, 
and perhaps at an earlier stage, and are most eﬀ  ective for 
tracking progression to a dementia state over time.
Cognitive measures
Despite the excitement about recent advances in the 
identiﬁ   cation of AD-related biomarkers, neuropsycho-
logical assessment remains a critical component of evalu-
ation to ensure a cognitive correlate of biomarker 
abnormalities and to assist in detecting and tracking 
progression of early AD. Neuropsychological evaluation 
provides both standardized and objective assessment of 
the hallmark feature of MCI and AD: the disturbance of 
memory and/or other cognitive functions – in particular, 
episodic memory deﬁ   cits as manifested by impaired 
delayed recall [10], faster rate of forgetting [11], and 
problems with learning new information [12]. Deﬁ  cits in 
delayed recall and other memory functions have been 
found to be predictive of cognitive decline in community-
dwelling older subjects [13] and of progression of MCI to 
dementia [14].
Deﬁ  cits in early AD, however, are not only limited to 
memory. Although memory dysfunction is typically the 
most common manifestation of early AD, some cases 
ﬁ   rst present with executive, language or visuospatial 
disturbances. It is widely accepted that memory impair-
ment across multiple memory measures or a combination 
of deﬁ  cits in memory and nonmemory measures have 
less reversion to normal and faster rates of progression to 
dementia than those with single amnestic or nonamnestic 
cognitive impairments [15]. Th  is suggests that multiple 
cognitive impairments or severity of deﬁ  cits in a single 
domain such as memory may be a proxy for the patient’s 
stage of illness. As noted in the new proposed guidelines 
for MCI related to AD [16], serial cognitive assessments 
of an individual in the MCI stage of AD allows for the 
assessment of cognitive decline over time and enhances 
conﬁ  dence in the progressive nature of the disorder and 
its underlying etiology. Techniques such as reliable 
change indices and consideration of practice eﬀ  ects are 
methods to measure meaningful change at an individual 
level, which can also be useful in analyzing the results of 
clinical trials [17].
In assessing the progression of mild cognitive impair-
ment to AD, it is imperative that MCI is correctly 
diagnosed and that these underlying cognitive impair-
ments  accurately reﬂ  ect the underlying AD pathology. 
Current challenges in the cognitive assessment of MCI 
include: test selection, the availability of normative 
databases, and the eﬀ  ect of diﬀ  erent base rates of MCI 
and AD in diﬀ  erent settings; establishing cut-oﬀ   points 
for impairment; and developing measures more sensitive 
to early AD while having suﬃ   cient speciﬁ  city to distin-
guish between etiologically diﬀ  erent conditions.
Methodologically, the lack of uniformity in the 
selection of neuropsychological measures and the use of 
diﬀ  erent normative databases often make it challenging 
to compare study results across settings and inter  nation-
ally. Further, diﬀ   erential base rates of true underlying 
cognitive impairment or AD pathology in older adults 
presenting to specialty memory disorder clinics com-
pared with a general medical practice or in epidemio-
logical settings may aﬀ   ect the diagnostic accuracy of 
neuropsychological tests. In general, a low prevalence or 
base rate of true cognitive impairment in a particular 
setting tends to reduce the positive predictive value or 
the probablility that a positive test represents true 
impairment while false negatives will remain low. In 
contrast, when the base rates of true cognitive 
impairment are high, the positive predictive value is high 
but there is an increased probability that a negative test 
will not reﬂ  ect a true absence of impairment.
Another challenge in cognitive assessment is the issue 
of cognitive reserve [18], which allows persons with 
diseased brains to use compensatory mechanisms that 
may mask overt manifestations of disease. Possible 
solutions to the problem of diagnosing cognitive impair-
ment in highly intelligent people is to apply appropriate 
norms for these subgroups, to develop more cognitively 
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diﬃ   cult or to employ test paradigms that allow within-
subject comparisons of diﬀ   erent aspects of memory 
(some of which are particularly vulnerable to early 
manifestations of AD).
Diagnostically,  the lack of standardization in cut-oﬀ   
points employed to determine impairment also creates 
discrepancies in the literature, which aﬀ  ects the ability to 
compare studies examining progression to speciﬁ  c 
endpoints among diﬀ   erent national and international 
research groups [19]. Many studies of amnestic mild 
cognitive impair  ment (aMCI) employ a 1.5 standard 
deviation cut-oﬀ    point relative to age and educational 
norms on one or more memory measures, with the 
realization that as the number of tests increases, there is a 
tendency towards false positives [20].  Other studies 
recommend using multiple memory measures but require 
a cut-oﬀ   point of 1.0 standard deviation below expected 
levels on at least two cognitive tests in the same cognitive 
domain [15]. In the current large ADNI-GO multisite 
neuroimaging study [21], provided that subjects meet 
clinical criteria for early MCI, educationally referenced 
scores on delayed paragraph recall at 0.5 to 1.0 standard 
deviation below expected levels are considered suﬃ   cient 
for inclusion as early aMCI. At the other extreme, an 
individual with objective memory impair  ment ≥3 standard 
deviations below expected levels may still be classiﬁ  ed as 
MCI if the clinician does not judge there to be suﬃ   cient 
impairments in social and/or occupational function to 
meet criteria for dementia. Indeed, in the new proposed 
criteria for MCI related to AD a range of impairment of 1.0 
to 1.5 standard deviations below expected levels on tests is 
typically expected on neuropsychological tests [16], but 
this is not a require  ment as more emphasis is placed on 
clinical history and examination. MCI as it is currently 
conceptualized therefore represents a wide range of 
individuals with varying severity of cognitive impairment. 
It naturally follows that the rate of progression to 
dementia, and an eventual AD state, may largely reﬂ  ect the 
degree of initial disease severity as measured by cognitive 
measures.
Speciﬁ  c patterns of cognitive impairments may not be 
speciﬁ   c to one disease entity.  Disorders such as AD, 
diﬀ  use Lewy body disease, cerebrovascular disorders and 
frontotemporal dementia are generally thought to have 
characteristic cognitive presentations in the early stages 
of disease but there can be considerable overlap in 
cognitive performance across disease entities. Th  is 
overlap problem is particularly salient in the two most 
common forms of dementia – AD and vascular dementia – 
where meta-analytic studies have found a limited ability 
of cognitive tests to distinguish between groups [22]. In a 
study of autopsy-deﬁ  ned subjects with cerebrovascular 
disease and AD, a majority of AD subjects exhibited a 
cognitive proﬁ  le characterized by memory impairment – 
but no reliable characteristic proﬁ  le existed for cerebro-
vascular disease [23]. Another meta-analysis comparing 
AD with fronto  temporal dementia showed signiﬁ  cant 
diﬀ  erences between groups on multiple measures, but 
the consider  able overlap between groups renders 
diﬀ   erential diag  nosis in individual cases diﬃ   cult  [24]. 
Similarly, there is considerable heterogeneity among 
individuals that limits speciﬁ   city in distinguishing 
between MCI of diﬀ  erent etiologies [25].
Tracking progression from MCI to dementia and an 
eventual diagnosis of AD requires cognitive measures 
sensitive to change over time. Although measures such as 
the Alzheimer’s Disease Assessment Scale (cognitive sub-
scale) have been employed in a number of large-scale 
pharma  cological studies of AD, there may be insuﬃ   cient 
sensitivity to change in early-stage MCI. For example, in 
the GEM study, the annual rate of change on the 
Alzheimer’s Disease Assessment Scale (cognitive sub-
scale) for MCI patients was considerably less than the 
degree of change considered clinically signiﬁ  cant in AD 
trials [26].
While there is currently a plethora of memory tests 
available, list-learning tests have the dual advantages of 
multiple learning trials and delayed recall. Dubois and 
colleagues contend that increased encoding speciﬁ  city at 
acquisition and assessed failure to beneﬁ  t from cuing at 
recall are superior to episodic memory tests using free 
recall alone in identifying early cases of AD [8]. Indeed, it 
has been previously shown that a primary deﬁ  cit  in 
proﬁ  ting from encoding cues at baseline and follow-up 
was superior to free recall and other traditional measures 
in detecting cognitive impairment [27]. Deﬁ  cits on the 
MCT, a test of controlled learning and cued semantic 
recall, were recently uniquely sensitive and related to the 
presence of [11C]Pittsburgh compound B (PiB) on PET 
scans in community older people [27]. Our group has 
found that list-learning tests employing distractor tasks 
between acquisition trials and competing lists enhancing 
susceptibility to semantic interference both have 
excellent sensitivity for MCI and are predictive of 
progression from MCI to dementia [12,20]. Th  e 
advantage of these aforementioned paradigms is that 
they target speciﬁ  c semantic memory processing deﬁ  cits 
that may be speciﬁ   c to early AD. Comparison of the 
individual’s performances on diﬀ   erent aspects of the 
same test seems well-suited to dealing with issues of high 
cognitive reserve. Although promising, future research is 
needed to determine the speciﬁ  city of such ﬁ  ndings to 
AD and their utility in serial assessments over time.
Functional assessment in mild cognitive impairment
An important concept in MCI has been the notion that 
functional activities of daily living should be intact [3]. 
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ment instruments is beyond the scope of this paper, 
research has increasingly shown that subjects with a 
formal diagnosis of MCI frequently have functional 
impairments. In aMCI patients, Instrumental Activities 
of Daily Living measures at baseline independently 
predicted progression to AD 1 year later [28]. Similarly, 
MCI subjects who progressed to AD 1 year later pre-
sented as more impaired on ﬁ  nancial capacity at baseline 
and had greater decline than nonprogressors [29]. A 
3-year longitudinal study of medical decision-making 
capacity showed that individuals with aMCI performed 
progressively worse in comprehending consent informa-
tion as compared with their own baseline performance 
and with a control group [9].
Studies of the relationship between neuropsychological 
test performance and functional ability have linked 
Activities of Daily Living deﬁ   cits and Instrumental 
Activities of Daily Living deﬁ   cits to global cognitive 
impairment [30], executive function and attention [31], 
and task-speciﬁ   c neuropsychological deﬁ   cits [32]. In 
most studies, however, neuropsychological measures 
have not explained the majority of the variability in 
functional measures, particularly in mildly impaired 
subjects. Th   is lack of explanation consequently suggests 
there is something unique about informant-based 
observations of real-world behaviors or the subject’s 
performance on performance-based tests that may not 
always be captured by neuropsychological tasks. A 
strength of informant report of cognitive deterioration is 
the ability to compare a subject’s performance with 
premorbid functioning so that true decline can be 
measured. Although decline can be inferred by baseline 
neuropsychological testing, it cannot be proven in the 
absence of serial cognitive evaluation.
Th  e Clinical Dementia Rating Scale (CDR) developed 
by John Morris was one of the ﬁ   rst validated clinical 
instruments to identify individuals in a predementia 
state, and a CDR score of 0.5 became known to indicate 
the early stages of AD preceding dementia [33]. Th  e  CDR 
is included here as a functional assessment measure in 
that it combines objective cognitive testing with the 
clinical assessment of six diﬀ  erent areas of daily function 
(memory, orientation, judgment, problem-solving, com-
mu nity  aﬀ   airs, and personal care) after an extensive 
interview with a knowledgeable informant. Th  e CDR is 
therefore unique in relating cognitive deﬁ   cits to real-
world consequences in everyday life, and is a widely used 
tool for clinical assessment of disease with longstanding 
demonstrated utility in diagnosis [34] and prediction of 
disease progression [35]. In a number of studies, 
progression to dementia has been delineated by change 
from a global CDR of 0.5 (questionable dementia) to a 
global CDR of 1.0 (mild dementia) or higher [36,37]. Th  e 
CDR sum of boxes has been demonstrated as a 
particularly sensitive method of monitoring progression 
of cognitive impairment over time [38]. Change in CDR 
scores or change in CDR sum of boxes has been used as 
an outcome measure in studies assessing the utility of 
various techniques for predicting progression from MCI 
to AD, including CSF biomarkers [39], morphometry 
[39], functional MRI [40], amyloid burden [41], and 
2-[18F]-ﬂ  uoro-2-deoxy-d-glucose (FDG)-PET [42].
Taken together, this evidence shows there are 
functional impairments in the MCI stage of AD that 
progressively become worse until the clinician has 
decided the individual has reached the threshold at which 
they meet the criteria for dementia. Once this threshold 
is crossed, the person has not converted to AD but has 
merely pro  gressed to a level of severity such that the 
cognitive deﬁ   cits have a profound impact on the 
individual’s life. Serial functional assessment is impor-
tant, however, in that it is essential for tracking disease 
progression, developing optimal strategies for symptom 
management, and attempting to enhance quality of life.
Biomarkers
Th   e recent criteria for MCI of Alzheimer’s type set forth 
by the National Institute of Aging Alzheimer’s Asso  cia-
tion workgroup propose that molecular biomarkers such 
as CSF Aβ-42, CSF tau/Aβ-42 ratio, p-tau/Aβ-42 ratio or 
amyloid load identiﬁ   ed by imaging are most probably 
related to the underlying pathology of AD [16]. Topo-
graphic measures such as hypometabolism or hypoper-
fusion on PET or single-photon emission computed 
tomography or medial temporal lobe atrophy support the 
diagnosis of AD, and may be particularly useful in 
monitoring disease progression.
Cerebrospinal fl  uid proteins
CSF biomarkers have been shown to diﬀ  erentiate 
between healthy controls and AD patients [43], and have 
utility in predicting progression from aMCI to AD [44] 
and from MCI to AD [45]. Th  e CSF Aβ-42/tau ratio 
diﬀ   erentiated patients with subjective cognitive com-
plaints, with non-aMCI, and with aMCI from healthy 
controls [46], was predictive of progression from aMCI 
to AD [46], was predictive of progression from controls 
to MCI [47], predicted cognitive decline in cognitively 
normal older adults [48], and diﬀ  erentiated between AD 
and vascular dementia [49]. Low Aβ-42/Aβ-40 ratios 
predicted even  tual development of MCI or AD at follow-
up 3 to 7 years later among cognitively normal commu-
nity volunteers [50]. A meta-analysis of CSF phosphory-
lated tau showed satisfactory clinical utility in diagnosing 
MCI and progression of MCI to dementia, but was less 
capable of diﬀ   erentiating AD from other types of 
dementia [51].
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number of the cardinal features of AD. CSF proteins 
predict the rate of cognitive decline in AD [52], in mild 
AD [53], and in healthy older adults [54]. CSF 
biomarkers are related to hippocampal atrophy [55] and 
postmortem neuritic plaques [56]. Th  e CSF Aβ-42/tau 
ratio also predicted the presence of postmortem 
neuritic plaques with a sensitivity of 91.6% and a 
speciﬁ  city of 87.5% in a mixed population including AD, 
other dementia, and other neurologic disease [56]. In a 
more recent study, CSF amyloid was found in 90% of 
AD patients, in 72% of MCI patients, and in 36% (a 6.88 
increased risk in apolipoprotein E4 carriers) of cogni  -
tively normal older people. Furthermore, 100% of 
subjects with MCI who progressed to AD and 94% of 
pathologically veriﬁ  ed AD patients could be identiﬁ  ed 
[57]. Despite impressive sensitivity, however, the 
speciﬁ  city was limited; and given the predominance of 
AD patients in the sample, it is diﬃ   cult to determine the 
ability of this biomarker to distinguish between etio-
logically distinct conditions.
Other studies have shown less promising results, such 
as the absence of a relationship between CSF proteins 
and disease progression [58]. CSF proteins were not 
associated with postmortem plaques and tangles in 50 
AD patients [59]. A multisite study of CSF biomarkers 
demonstrated that although Aβ-42, p-tau, and total tau 
predicted progression from MCI to AD, a receiver-
operating characteristic curve analysis was only modestly 
accurate at 0.78 for Aβ-42, 0.76 for p-tau, and 0.79 for 
total tau [60]. A meta-analysis found that CSF biomarkers 
were less sensitive than episodic memory scores in 
detecting preclinical AD [10]. Altogether, CSF bio-
markers appear to have considerable promise in early 
detection of AD – but more work is required to optimize 
their contribution.
Neuroimaging
Given the prominence of the amyloid hypothesis of AD, 
the ability to detect β-amyloid accumulation in vivo in 
the brain has generated excitement about the possibility 
of earlier AD detection. PiB-PET imaging of amyloid 
deposition has been associated with cortical atrophy [61], 
glucose metabolism [62], CSF biomarkers [63], eventual 
development of AD in cognitively normal older adults 
[41], default mode network connectivity [64], CDR sum 
of boxes score [65], cognitive decline [61], and episodic 
memory [37]. Recent studies have shown that PiB may be 
useful in detecting preclinical AD [41,61] and in 
predicting the progression from MCI to AD [66]. PiB-
PET imaging is also being studied to determine its 
usefulness in distinguishing diagnostic categories [67], 
and has shown the ability to distinguish between aMCI 
and non-aMCI [68].
Although PiB-PET imaging techniques are correlated 
to many of the key aspects and biomarkers of AD, there 
may be limitations to their usefulness. Most importantly, 
amyloid deposition has been found in a signiﬁ  cant 
percentage of cognitively normal older subjects [69]. 
Further, a range of studies have failed to replicate associa-
tions between amyloid deposition and clinical measures 
[70], cognition [69], FDG-PET [71], and hippocampal 
atrophy in AD [69]. Cognitive reserve and the ﬁ  nding 
that amyloid appears well before cognitive symptoms 
may explain some of the discrepancies in the literature 
[27]. Also, PiB uptake appears to be nonspeciﬁ  c for AD, 
as it has been shown to be elevated in Parkinson’s 
dementia [72] and in Lewy body disease [73].
In addition to measuring amyloid burden, FDG-PET 
imaging has been employed to study regional and global 
variations in cortical activity in AD progression. FDG-
PET hypometabolism has been associated with amyloid 
burden [62], CSF biomarkers [74], maternal history of 
AD [75], apolipoprotein E4 status in healthy adults [76], 
verbal memory test decline [77], memory test perfor-
mance [78], and perceived memory loss [79]. Regional 
variations in glucose metabolism have also correlated 
with progression from pre-MCI to MCI [77] and from 
aMCI to AD [78]. Diagnostically, FDG-PET increases 
statistical power over cognitive measures [67] and has 
superior diagnostic sensitivity (0.84) and speciﬁ  city (0.74) 
to an initial clinical evaluation [80]. FDG-PET success-
fully identiﬁ  ed diﬀ  erent metabolic patterns in AD and 
cerebrovascular disease [81] and assisted in distin-
guishing between AD and frontotemporal dementia [82].
In addition to PET imaging, longitudinal volumetric 
neuroimaging with MRI has identiﬁ  ed brain regions that 
tend to manifest neuronal loss early in the course of MCI. 
Research has demonstrated changes in medial temporal 
lobe structures in subjects with MCI [83] or in subjects 
with aMCI who progress to dementia [84]. Other brain 
regions implicated in disease progression include the 
anterior and posterior cingulate gyrus, precunus, and 
frontal lobes [84]. Recent work has also investigated the 
utility of functional MRI to predict progression of 
cognitive decline in MCI [40]. Research has shown that 
there is a prodromal period in AD in which there is stable 
decline, followed by more rapid cognitive and structural 
changes in the 2 to 3 years prior to the expression of 
clinical symptomatology [85]. Similarly, Carlson and 
colleagues showed that rates of ventricular volume 
expansion are greater in subjects who go on to develop 
MCI, and that the rate of expansion increases in the 2 to 
3 years prior to clinical MCI diagnosis [86].
Taken together, CSF biomarkers, FDG-PET, and MRI 
studies have shown considerable promise in identifying 
early AD and monitoring the disease progression through 
the clinical stages to dementia. New techniques that 
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possibility of detection of disease in its earliest possible 
stages but may not be as useful as cognitive measures, 
imaging techniques or other biomarkers for monitoring 
changes in the brain that occur between the MCI and 
dementia stages of AD. Th   e use of these techniques also 
raises an important issue. Signiﬁ   cant percentages of 
cognitively normal older people may have AD pathology 
but do not manifest cognitive symptoms during life [69], 
and many cases of MCI have non-AD pathology. 
Assessment tools with high speciﬁ  city in early detection 
are needed to facilitate early intervention of AD. Despite 
the understandable excitement that biomarkers provide, 
it will be important to be appro  priately cautious 
regarding the application of these new techniques to 
clinical care and practice until the techniques can be 
established as speciﬁ  c to AD [87].
Conclusion
While lauding a decade of eﬀ   orts to delineate sub-
classiﬁ  cations of AD, it is important to emphasize that 
AD remains a single disease entity throughout all its 
stages. Consequently, movement from stage to stage 
signiﬁ  es disease progression on a continuum (which is 
not always linear), rather than a conversion from one 
entity to another. Nonetheless, eﬀ   orts to diﬀ  erentiate 
disease stages have considerable utility, particularly in 
research, and it is imperative to establish greater 
uniformity in assessment, cut-oﬀ   points, and diagnostic 
criteria to more meaningfully compare the results of 
national and international research eﬀ  orts.  Th  e new 
proposed National Institute of Aging Alzheimer’s 
Association guidelines for the diagnosis of AD recognize 
the need to identify preclinical AD as well as MCI due to 
AD [16]. Th  ese new criteria will undoubtedly stimulate 
the further research needed in the area.
Based on current evidence, we brieﬂ  y summarize our 
views on how to best study the progression of deﬁ  cits 
associated with the MCI stage of early AD as follows.
First, conversion to dementia has typically been used as 
a primary endpoint to judge treatment eﬀ   ects in AD 
although this may not be the optimal way to study 
progression in a disorder that falls on a continuum, 
particularly as attempts are made to treat the disorder in 
its earliest stages. Given their continuous nature, 
objective cognitive measures will probably be among the 
more useful measures for assessing AD progression and 
monitoring response to the earliest interventions.
Second, memory measures assessing learning over 
multiple trials with delayed recall are among the most 
powerful cognitive measures in early detection and 
monitoring of early AD, but nonmemory measures – 
particularly those tapping executive function, language 
and visual–spatial skills – should be employed in serial 
assessment of MCI. In addition, ratings of cognitive and 
functional change – particularly those observed by 
skilled clinicians and knowledgeable informants over 
time – can provide critical information. Further develop-
ment of newer paradigms that focus on encoding speci-
ﬁ  city, deﬁ  cits in semantic memory processing, dysexecu-
tive function, and the use of techniques such as reliable 
change analyses will be useful in detecting early impair-
ment and gauging meaningful changes in performance 
over time.
Th  ird, the presence of speciﬁ   c CSF biomarkers, the 
amyloid load in the brain, and speciﬁ  c patterns of brain 
hypometabolism or atrophy make it much more likely 
that cases of both early and later MCI represent early AD, 
which will be critical to the development of early clinical 
intervention studies. Further, serial assessment of these 
neuroimaging markers such as PET and MRI may have 
particular utility in assessing longitudinal change or 
response to intervention.
Finally, since each method provides unique information 
and variance, it is likely that a combination and statistical 
weighting of diﬀ  erent biomarkers and neuropsychological 
tests across serial assessments will provide the most 
robust predictor at both the group and individual levels. 
For instance, combined FDG-PET and PiB-PET imaging 
has been shown capable of distinguishing between 
control, MCI, and AD subjects better than either tech-
nique in isolation [88]. Similarly, a recent study demon-
strated that combined FDG-PET and episodic memory 
scores predicted progression from MCI to AD better 
than either measure alone [89].
Newly emerging technologies to study brain function 
have generated considerable enthusiasm. While sensi-
tivity to early AD is critical, speciﬁ   city to the neuro-
pathology of the disorder and the ability to diﬀ  erentiate 
between diﬀ   erent etiological conditions is critically 
important. Identifying the best combination of predictors 
of eventual clinical outcomes and the optimal means of 
utilizing these predictors are the most important 
challenges for future research.
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